首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1402085

全球特應性濕疹治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Atopic Eczema Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年12月01日 | 出版商:

Value Market Research | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球特應性濕疹治療市場的市場規模將從 2022 年的 112.9 億美元達到近 211.9 億美元，2023-2030 年研究期間CAGR為 8.19%。

異位性濕疹或異位性皮膚炎是一種持續性皮膚病，其特徵是皮膚乾燥、搔癢和發炎。異位性濕疹的治療旨在緩解症狀、減少發炎並預防發作。

市場動態

全球特應性濕疹發生率的增加促使對有效治療的需求不斷增加。正在進行的研究和開發計劃不斷引入創新療法，包括先進的藥物傳輸系統和生物製劑，以提高治療效果。技術進步進一步促進了對患者更友善的解決方案的創建。全球不斷成長的醫療保健支出使人們能夠更廣泛地獲得先進的治療，而患者和醫療保健提供者的意識提高則有助於及早診斷和開始治療。政府的支持政策和研究經費鼓勵開發更多療法，促進市場成長。此外，競爭激烈的市場格局鼓勵藥物創新，從而產生更廣泛的治療選擇。此外，基於個別患者特徵的個人化醫療和客製化治療的趨勢推動了更有針對性的療法的創建。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球特應性濕疹治療市場的各個細分市場進行了包容性評估。特應性濕疹治療產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲特應性濕疹治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。特應性濕疹治療市場的主要參與者包括輝瑞公司、艾伯維公司、GALDERMA LABORATORIES, LP、大塚製藥有限公司、再生元製藥公司、因塞特公司、賽諾菲、諾華公司、禮來公司（Dermira）、LEO Pharma Inc. 等。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：特應性濕疹治療公司的競爭格局

特應性濕疹治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

GALDERMA LABORATORIES LP

公司簡介
公司收入
產品
最近的發展

Otsuka Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Regeneron Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Incyte Corporation

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company (Dermira)

公司簡介
公司收入
產品
最近的發展

LEO Pharma Inc

公司簡介
公司收入
產品
最近的發展

其他
- 公司簡介
- 公司收入
- 產品
- 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112987

The global demand for Atopic Eczema Treatment Market is presumed to reach the market size of nearly USD 21.19 BN by 2030 from USD 11.29 BN in 2022 with a CAGR of 8.19% under the study period 2023 - 2030.

Atopic eczema or atopic dermatitis is a persistent skin condition marked by dry, pruritic (itchy), and inflamed skin. Treatment for atopic eczema aims to alleviate symptoms, reduce inflammation, and prevent flare-ups.

MARKET DYNAMICS

Increasing incidences of atopic eczema worldwide prompt a rising demand for effective treatments. Ongoing research and development initiatives continuously introduce innovative therapies, including advanced drug delivery systems and biologics, enhancing treatment efficacy. Technological advancements further enable the creation of more patient-friendly solutions. Rising healthcare expenditure globally allows broader access to advanced treatments, while heightened awareness among patients and healthcare providers leads to early diagnosis and treatment initiation. Supportive government policies and funding for research encourage the development of more therapies, fostering market growth. Additionally, a competitive market landscape encourages pharmaceutical innovation, resulting in a wider array of treatment options. Moreover, the trend toward personalized medicine and tailored treatments based on individual patient characteristics drives the creation of more targeted therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of atopic eczema treatment. The growth and trends of atopic eczema treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the atopic eczema treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Biologics
PDE4 Inhibitors

By Route Of Administration

Topical
Injectable
Oral

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Atopic Eczema Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Atopic Eczema Treatment market include Pfizer Inc., AbbVie Inc., GALDERMA LABORATORIES, L.P., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Sanofi, Novartis AG, Eli Lilly and Company (Dermira), LEO Pharma Inc., and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ATOPIC ECZEMA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Biologics Historic and Forecast Sales by Regions
5.5 PDE4 Inhibitors Historic and Forecast Sales by Regions

6 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1 Overview by Route of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Route of Administration
6.4 Topical Historic and Forecast Sales by Regions
6.5 Injectable Historic and Forecast Sales by Regions
6.6 Oral Historic and Forecast Sales by Regions

7 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ATOPIC ECZEMA TREATMENT COMPANIES

8.1. Atopic Eczema Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ATOPIC ECZEMA TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. AbbVie Inc.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GALDERMA LABORATORIES L.P.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Otsuka Pharmaceutical Co. Ltd.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Regeneron Pharmaceuticals Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Incyte Corporation
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Sanofi
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Novartis AG
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Eli Lilly and Company (Dermira)
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. LEO Pharma Inc
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Others
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments